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Multiple Sclerosis (MS) is a chronic inflammatory
disease of the central nervous system characterized
by successive exacerbations over its course.
Epidemiological studies have established that
the prevalence of MS varies considerably across
geographic areas. Prevalence estimates vary from
20 to 180 per 100,000 inhabitants in studies of
northern developed countries. Reasons for these
differences are not known. The prevalence of MS
is highest in northern Europe, southern Australia,
and the middle part of North America [1]. Esti-
mates suggest that there are currently 250,000 to
350,000 MS patients in the United States.
 
MS generates many physical and social impair-
ments of varying severities. Physical symptoms and
limitations are often associated with social ones in
connection with loss of productivity at work, long
 
periods off work, and an important burden for fam-
ilies. These features are accentuated by the relatively
 
young average age of onset of the disease, at 30 years.
 
The recent availability of interferon beta and glat-
iramer acetate for treatment of MS has raised con-
cerns among medical decision makers and payers
with regard to their efficacy, the magnitude of side
effects, public expectations for their widespread use,
and the high expected cost of such treatments [2].
Therefore there is an urgent need for cost-effective-
ness data to provide guidelines for the optimal choice
of available treatment strategies. Such data are par-
ticularly useful in the case of MS, where opinions
about appropriate medical management vary greatly
among clinicians based on the specific clinical charac-
teristics and medical history of each patient [1,3,4].
In the last decade, several cost-of-illness studies
of MS have been published in the international lit-
erature [5–7]. The results have been consistent in
underscoring the importance of indirect costs in
MS patients. However, these studies have also
demonstrated the methodological difficulties in
evaluating indirect costs in a credible and generally
accepted manner. The quantification or valuation
of indirect costs is one of the areas of great contro-
versy in health economics. Furthermore, the gener-
ally accepted methods for evaluation of indirect
costs have not gained widespread acceptance
among decision makers and other practitioners.
Regarding direct costs, previous studies have
shown that the clinical category (relapsing-remit-
ting and secondary progressive MS) and extent of
the physical disability are highly predictive of the
medical costs. Direct costs are highly heteroge-
neous, however, of over the course of the disease.
Initially, costs are primarily related to routine
treatment and inpatient care for relapses; as the
disease progresses, the loss of functional auton-
omy becomes the main determinant of care.
More recently, a number of cost-effectiveness
studies of treatment, mainly with interferon beta,
 
have been published [8,9], and this issue of 
 
Value in
 
Health
 
 presents an important new study on this topic
by Mark Nuijten and John Hutton. These studies ap-
pear at a time when the efficacy of all registered drugs
has been demonstrated in phase III clinical trials.
The clinical data currently available for treat-
ment efficacy are sufficiently well documented to
allow for economic evaluations. Nevertheless, im-
portant questions that challenge the development
of pharmacoeconomic evaluations of MS treat-
ment strategies remain unanswered. We will dis-
cuss some of these questions below.
Ideally, economic modeling of treatment strate-
gies should include the entire treatment time frame.
In the case of MS, long-term effectiveness and safety
data for treatments are not available. In existing clin-
ical trials, the follow-up period does not exceed 3 to
5 years, which is considerably shorter than the ex-
pected survival of patients with MS (typically, more
than 30 years). Economic models provide tools for
extrapolating from the observed data, which makes
the exercise somewhat speculative, especially over
longer periods of time. In addition, the choice of an
appropriate time frame often presents unique chal-
lenges. The recent debate [10] surrounding the UK-
NICE committee’s conclusions on the use of inter-
feron beta and glatiramer acetate in MS illustrates
the problems that can arise regarding the choice of a
relevant time frame: Should it be 10 years, 20 years,
or a lifetime, as in the paper presented in this issue?
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The choice is not merely scientific because it relates
to several different domains discussed below.
Extrapolating from short-term efficacy, as mea-
sured in clinical trials, to long-term effectiveness is
particularly complicated for MS, a disease of un-
known etiology with variable pathophysiologic
features and a highly unpredictable evolution. The
primary outcome measures in clinical studies (de-
gree of disability, relapse rate, time to progression)
may not be predictive of long-term evolution.
Another set of issues relates to discounting. At the
moment, there is no general consensus among inter-
national economists regarding the use of discount-
ing. Controversy exists as to whether discounting
should be applied to both costs and benefits or only
to costs, and what discount rate is appropriate. Dis-
counting tends to greatly diminish long-term costs
and benefits, especially when a discount rate of 6%
is applied, as is recommended in the United King-
dom. It seems paradoxical, although understandable
from an academic perspective, to simultaneously ap-
ply high discount rates to the cost benefits of a long-
term treatment rather than to consider a short-term
treatment horizon without discounting when the
long-term effects of the treatment occur at the time
of treatment delivery.
Furthermore, therapeutic innovations are likely
to emerge and compete with current experimental
treatments, which may weaken the case for consid-
ering a very lengthy time frame for economic analy-
ses of treatment strategies. This may be particularly
true for MS, which is an area of active medical re-
search. Finally, there is also controversy regarding
the effect of treatment after its discontinuation.
One area of uncertainty relates to the natural
history of MS. In the absence of data from large co-
hort studies, modeling of the temporal evolution of
MS is often based on information from clinical tri-
als. However, such data may not be representative
of the evolution of MS in the general population.
Furthermore, while the Expanded Disability Status
Scale (EDSS) introduced by Kurtzke in 1983 al-
lowed for standardization of handicap assessment
by clinicians and is now universally used, it has cer-
tain limitations. The scale has been criticized for its
large interrater variability [11], its ordinal nature,
and its unnecessary focus on certain categories of
functional impairment. Its use for economic mod-
 
eling seems unavoidable but its limitations raise
issues regarding the validity of results. Another un-
certainty concerns the assumptions used for model-
ing of disease progression. Most models assume
only stabilization or progressive worsening of the
disease over time. However, improvement as well
as sudden major deterioration may also occur and
must therefore be incorporated in the models.
In the field of outcomes research, economic
modeling is increasingly used for the assessment of
expensive treatments in various settings. The case
of interferon beta in MS is an interesting example
of the different challenges that analysts face in such
an exercise. An important and difficult task is to
improve the communicability of such studies. Even
trained professionals often find it difficult to fully
understand the inner workings of economic mod-
els, which inevitably appear to be “black boxes.”
Hence, readers often have to trust the quality of the
work based on the reputations of the authors, the
reviewers, and the journals. At the same time, the
ultimate role of modeling is to provide a synthesis
of all relevant information and serve as a guideline
for decision making. The challenge then becomes
finding the appropriate compromise between sim-
plicity and scientific credibility in this exercise.
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